CLIA: Advancement and market dynamic

With the combination of the basic principle of radioimmunoassay, high sensitive chemiluminescence and high specific immunoassay, the year 1977 saw the emergence of a new technology-Chemiluminescence Immunoassay (CLIA) which provided one of the best solutions for the quantification of specimens from a complex mixture with the non-radioactive nature, making it an advantage to replace RIA in multiple immunoassay applications in in vitro diagnostic industry. Multiple factors have constituted the vast and rapid development of Chemiluminescence Immunoassays in the global IVD industry.

Overseas Technical Director - Alex Xu
Overseas Technical Director - Alex Xu

 1. High technical barrier

The priority of in vitro diagnosis lies on the accuracy of a test result which attributes to the integration of instrument, reagent, international standard reference materials. Any difference among them could lead to the discrepancy of test results. Chemiluminescence Immunoassay systems, given the nature of the active proteins such as antigen and antibody in reagent components, have to be used with the corresponding reagents manufactured by the same manufacturer. Therefore, most of automated CLIA systems are closed systems. As closed systems, the integration of interdisciplinary disciplines including biomedical science, engineering, automation, immunology and the vast investment and quality control in instruments as well as reagent sets an extremely high technical barrier for research and development of CLIA systems. As a result, relatively fewer manufacturers command the market share of CLIA market.

2. Comprehensive application

With the research and development of more and more immunoassay markers, the comprehensive test menu and various applications boost the rapid development of CLIA systems in IVD market. At present, the applications of CLIA consist of tumor markers, infectious diseases, endocrines and so forth. The number of assays available so far for a CLIA system with the largest test menu is more than 120. There is no denying that, with such varied applications in one automated system, CLIA systems are rather appealing to all sorts of laboratories and hospitals.

3.Market trend

With a higher demand of an integrated system to process a vast quantity of samples for tests of biochemistry, immunoassay, electrolytes, integrated systems with the combination of biochemistry, CLIA and electrolyte modules are appealing in large-scale laboratories. The emerging need for sophisticated integrated system urges the research and development of CLIA systems, which are able to integrate with other modules and have a larger test menu, to become trending in the IVD market.



Read all latest stories

Related articles


Video • Equipment fair

Impressions from CMEF 2018

We were at the spring 2018 China International Medical Equipment Fair (CMEF) in Shanghai and had a good look at the many exciting devices the exhibitors had on show.

Click here to see…


Article •

An international impact on immunoassay

Snibe, the Shenzhen New Industries Biomedical Engineering Company Ltd., is a leading Chinese biomedical technology company dedicated to developing and manufacturing clinical laboratory equipment and…


News • Presented at ESCMID Global

Immunoassay analyzer extends menu with new hepatitis assays

Beckman Coulter Diagnostics announced ahead of the ESCMID Global congress (formerly ECCMID) that it has extended the menu of DxI 9000 Immunoassay Analyzer* assays.

Related products

Subscribe to Newsletter